Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maureen Dubreuil

Showing results (1-10 of 81) with videos related to

Pageof 9
Sort By:
Current Rheumatology Reports|February 10, 2024
Year in Review in Axial Spondyloarthritis Clinical Research and Guidelines: SPARTAN 2023 Annual Meeting ProceedingsMaureen Dubreuil
Arthritis & Rheumatology (Hoboken, N.J.)|February 23, 2018
Editorial: Inflammatory Back Pain and Axial Spondyloarthritis: Lessons for Clinical Practice and Epidemiologic ResearchMaureen Dubreuil, Joachim Sieper
Current Opinion in Rheumatology|April 5, 2017
Axial spondyloarthritis classification criteria: the debate continuesMaureen Dubreuil, Atul A Deodhar
Lancet (London, England)|July 31, 2022
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritisJean W Liew, Maureen Dubreuil
Rheumatic Diseases Clinics of North America|April 29, 2020
Treat to Target in Axial Spondyloarthritis: Pros, Cons, and Future DirectionsJean W Liew, Maureen Dubreuil
Current Opinion in Rheumatology|May 11, 2021
Educational needs and challenges in axial spondyloarthritisAnand Kumthekar, Mohamad Bittar, Maureen Dubreuil
Family Medicine|April 4, 2009
Enhancing the hospice curriculum within the family medicine clerkshipHugh Silk, Catherine M Weber, Maureen Dubreuil
Current Opinion in Rheumatology|April 5, 2017
Minimal disease activity in axial spondyloarthritis: the need of the hour and a proposal for developmentAtul A Deodhar, Anand Kumthekar, Maureen Dubreuil
Immunotherapy|September 7, 2023
The role of upadacitinib for the treatment of axial spondyloarthritisNavya George, Jean W Liew, Maureen Dubreuil
The Journal of Rheumatology|March 15, 2025
Diversity in Axial Spondyloarthritis Drug Trials: Enrollment by Sex, Race, Ethnicity, and Geographic RegionMathieu Choufani, Wissam Ghusn, Maureen Dubreuil, et al.
Pageof 9

Showing results (1-10 of 81) with videos related to

Sort By:
Pageof 9
Current Rheumatology Reports|February 10, 2024
Year in Review in Axial Spondyloarthritis Clinical Research and Guidelines: SPARTAN 2023 Annual Meeting ProceedingsMaureen Dubreuil
Arthritis & Rheumatology (Hoboken, N.J.)|February 23, 2018
Editorial: Inflammatory Back Pain and Axial Spondyloarthritis: Lessons for Clinical Practice and Epidemiologic ResearchMaureen Dubreuil, Joachim Sieper
Current Opinion in Rheumatology|April 5, 2017
Axial spondyloarthritis classification criteria: the debate continuesMaureen Dubreuil, Atul A Deodhar
Lancet (London, England)|July 31, 2022
Upadacitinib for the treatment of active non-radiographic axial spondyloarthritisJean W Liew, Maureen Dubreuil
Rheumatic Diseases Clinics of North America|April 29, 2020
Treat to Target in Axial Spondyloarthritis: Pros, Cons, and Future DirectionsJean W Liew, Maureen Dubreuil
Current Opinion in Rheumatology|May 11, 2021
Educational needs and challenges in axial spondyloarthritisAnand Kumthekar, Mohamad Bittar, Maureen Dubreuil
Family Medicine|April 4, 2009
Enhancing the hospice curriculum within the family medicine clerkshipHugh Silk, Catherine M Weber, Maureen Dubreuil
Current Opinion in Rheumatology|April 5, 2017
Minimal disease activity in axial spondyloarthritis: the need of the hour and a proposal for developmentAtul A Deodhar, Anand Kumthekar, Maureen Dubreuil
Immunotherapy|September 7, 2023
The role of upadacitinib for the treatment of axial spondyloarthritisNavya George, Jean W Liew, Maureen Dubreuil
The Journal of Rheumatology|March 15, 2025
Diversity in Axial Spondyloarthritis Drug Trials: Enrollment by Sex, Race, Ethnicity, and Geographic RegionMathieu Choufani, Wissam Ghusn, Maureen Dubreuil, et al.
Pageof 9